EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network homepage

Menu

Members

Armand Bensussan

Name of the laboratory

Immunology, Dermatologie & Oncology
INSERM U976
Hôpital Saint Louis
Equerre Bazin
1 Avenue Claude Vellefaux
75475 Paris cedex 10, France
33 153 722 081

Members of the laboratory

Members: Immunology, Dermatologie and Oncology
Head of the Unit
Armand Bensussan armand.bensussan@inserm.fr
Researchers
Martine Bagot martine.bagot@aphp.fr
Anne Marie-Cardine anne.marie-cardine@inserm.fr
Laurence Michel laurence.michel@inserm.fr
Reem Al Daccak reem.al-daccak@inserm.fr
Gérard Chaouat gerard_chaouat@wanadoo.fr
Céleste Lebbé celeste.lebbe@aphp.fr
Nicolas Dumaz nicolas.dumaz@inserm.fr
Nicole Basset-Seguin nicole.basset-seguin@aphp.fr
Vincent Descamps vincent.descamps@aphp.fr
Sébastien Jauliac sebastien.jauliac@inserm.fr
Isabelle Petit isabelle.petit@inserm.fr
Daniel Aberdam daniel.aberdam@inserm.fr
Samia Mourah samia.mourah@aphp.fr
Caroline Ram-Wolff caroline.ram-wolff@aphp.fr
Ph.D. Students
Anne Caudron anne.caudron@inserm.fr
Florence Laugier florence.laugier@inserm.fr
Adèle De Masson adele.demasson@aphp.fr
Charlotte Hurabielle charlotte.hurabielle@gmail.com
Lauriane Roux lauriane.roux@inserm.fr
Technicians
Nicolas Thonnart nicolas.thonnart@inserm.fr
Valérie Dessirier valerie.dessirier@inserm.fr
Jocelyne André jocelyne.andre@inserm.fr
Edith Aberdam edith.aberdam@inserm.fr
Gabrielle Larcheron gabrielle.larcheron@inserm.fr
Frédéric Guaddachi frederic.gaddachi@inserm.fr
Valérie Schiavon valerie.schiavon@inserm.fr

Laboratory activity

Our laboratory is located at Saint Louis Hospital in Paris. We are working on the identification of new targets for the diagnosis and the therapy of skin diseases. Monoclonal antibodies are essential tools for determining the identification of these molecules. Dr. Armand Bensussan is the president of the French Association of Immunology, he is a member of the International HCDM (Human Cell Differentiation Molecules) Council.

Research activities

1. Physiopathology of Cutaneous T cell Lymphoma & Receptors of Innate Immunity

2. Oncogenesis of Melanoma

3. Epithelial pathophysiology, stem cells & tissue repair

Techniques available

  • Monoclonal antibody production in mice
  • Antibodies characterization
  • Multi-colour flow cytometry
  • Immunization with transfected cells

Publications (2019-present)

  • Bensussan A, Marie-Cardine A. (2018) CD160. In Encyclopedia of Signaling Molecules. Ed : S. Choi, Springer. Second Edition, p. 846-852.
  • Hurabielle C, Leboeuf C, Ram-Wolff C, Meignin V, Rivet J, Vignon-Pennamen MD, Bonnafous C, Sicard H, Fite C, Raffoux E, Arnulf B, Oksenhendler E, de Fontbrune FS, de Latour RP, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Janin A, Bagot M, Battistella M. KIR3DL2 expression in patients with adult T-cell lymphoma/leukemia. Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16322.
  • Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R. Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. Sci Rep. 2017 Mar 16;7:44720. doi: 10.1038/srep44720.
  • Michel L, Reygagne P, Benech P, Jean-Louis F, Scalvino S, Ly Ka So S, Hamidou Z, Bianovici S, Pouch J, Ducos B, Bonnet M, Bensussan A, Patatian A, Lati E, Wdzieczak-Bakala J, Choulot JC, Loing E, Hocquaux M. Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signaling pathways. Br J Dermatol. 2017 Apr 12. doi: 10.1111/bjd.15577. [Epub ahead of print]
  • Roelens M, Delord M, Ram-Wolff C, Marie-Cardine A, Alberdi A, Maki G, Homyrda L, Bensussan A, Bagot M, Toubert A, Moins-Teisserenc H. Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity. Blood. 2017 Jul 31. pii: blood-2017-03-772996. doi: 10.1182/blood-2017-03-772996.
  • Garbar C, Mascaux C, Giustiniani J, Merrouche Y, Bensussan A. Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231. Sci Rep. 2017 Aug 3;7(1):7201. doi: 10.1038/s41598-017-07489-x.
  • Le Bouteiller P, Bensussan A. Up-and-down immunity of pregnancy in humans. F1000Res. 2017 Jul 25;6:1216. doi: 10.12688/f1000research.11690.1. eCollection 2017. Review.
  • Schmitt C, Marie-Cardine A, Bensussan A. Therapeutic antibodies to KIR3DL2 and other target antigens on cutaneous T-cell lymphomas. Front Immunol. 2017 Aug 30;8:1010. doi: 10.3389/fimmu.2017.01010. eCollection 2017. Review.
  • Battistella M, Leboeuf C, Ram-Wolff C, Hurabielle C, Bonnafous C, Sicard H, Bensussan A, Bagot M, Janin A. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Blood. 2017 Oct 31. pii: blood-2017-06-792382. doi: 10.1182/blood-2017-06-792382.
  • Dam N, Hocine HR, Palacios I, DelaRosa O, Menta R, Charron D, Bensussan A, El Costa H, Jabrane-Ferrat N, Dalemans W, Lombardo E, Al-Daccak R. Human Cardiac-Derived Stem/Progenitor Cells Fine-Tune Monocyte-Derived Descendants Activities toward Cardiac Repair. Front Immunol. 2017 Oct 26;8:1413. doi: 10.3389/fimmu.2017.01413. eCollection 2017.
  • Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N. The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway. Oncotarget. 2017 Dec 6;8(69):113360-113372. doi: 10.18632/oncotarget.23008. eCollection 2017 Dec 26.
  • Brun C, Jean-Louis F, Oddos T, Bagot M, Bensussan A, Michel L. Phenotypic and functional changes in dermal primary fibroblasts isolated from intrinsically aged human skin. Exp Dermatol, 2016 Feb;25(2):113-9. doi: 10.1111/exd.12874. Epub 2016 Jan 11.
  • Hu HH, Kannengiesser C, Lesage S, André J, Mourah S, Michel L, Descamps V, Basset-Seguin N, Bagot M, Bensussan A, Lebbé C, Deschamps L, Saiag P, Leccia MT, Bressac-de-Paillerets B, Tsalamlal A, Kumar R, Klebe S, Grandchamp B, Andrieu-Abadie N, Thomas L, Brice A, Dumaz N, Soufir N. PARKIN Inactivation Links Parkinson's Disease to Melanoma. J Natl Cancer Inst, 2015 Dec 17;108(3). pii: djv340. doi: 10.1093/jnci/djv340. Print 2016 Mar.
  • Hurabielle C, Michel L, Ram-Wolff C, Battistella M, Jean-Louis F, Beylot-Barry M, d'Incan M, Bensussan A, Bagot M. Expression of Sézary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides. J Invest Dermatol, 2016 Jan;136(1):317-20. doi: 10.1038/JID.2015.360.
  • Lédée N, Petitbarat M, Chevrier L, Vitoux D, Vezmar K, Rahmati M, Dubanchet S, Gahéry H, Bensussan A, Chaouat G. The Uterine Immune Profile May Help Women With Repeated Unexplained Embryo Implantation Failure After In Vitro Fertilization. Am J Reprod Immunol, 2016 Jan 18. doi: 10.1111/aji.12483. [Epub ahead of print
  • Joffre J, Hau E, Zeboudj L, Laurans L, Battistella M, Boufenzer A, de Masson A, Le Buanec H, Cochaud S, Bagot M, Bensussan A, Gibot S, Bouaziz JD, Ait-Oufella H. Trem-1 is not crucial in psoriasiform imiquimod-induced skin inflammation in mice. Exp Dermatol, 2016 Jan 19. doi: 10.1111/exd.12944. [Epub ahead of print]
  • Boonk SE, Zoutman WH, Marie-Cardine A, van der Fits L, Out-Luiting JJ, Mitchell TJ, Tosi I, Morris SL, Moriarty B, Booken N, Felcht M, Quaglino P, Ponti R, Barberio E, Ram-Wolff C, Jäntti K, Ranki A, Bernengo MG, Klemke CD, Bensussan A, Michel L, Whittaker S, Bagot M, Tensen CP, Willemze R, Vermeer MH. Evaluation of immunophenotypic and molecular biomarkers for Sézary syndrome using standard operating procedures: multicenter study of 59 cases. J Invest Dermatol, 2016 Feb 27. doi: 10.1016/j.jid.2016.01.038.
  • Laugier F, Delyon J, André J, Bensussan A, Dumaz N. Hypoxia and MITF regulate KIT oncogenic properties in melanocytes. Oncogene. 2016 Mar 14. doi: 10.1038/onc.2016.39. [Epub ahead of print]
  • Chasset F, De Masson A, Le Buanec H, Xhaard A, Sicre de Fontbrune F, Robin M, Rybojad M, Parquet N, Brignier AC, Coman T, Bengoufa D, Bergeron A, Peffault de Latour R, Bagot M, Bensussan A, Socie G, Bouaziz JD. APRIL levels are associated with disease activity in human chronic graft versus host disease. Haematologica. 2016 Mar 18. pii: haematol.2016.145409. [Epub ahead of print]
  • de Masson A, Bouaziz JD, Battistella M, Bagot M, Bensussan A. Immunopathology of psoriasis: from bench to bedside. Med Sci (Paris), 2016, 32(3):253-9. doi:10.1051/medsci/20163203009. Epub 2016 Mar 23.
  • Battistella M, Janin A, Jean-Louis F, Collomb C, Leboeuf C, Sicard H, Bonnafous C, Dujardin A, Ram-Wolff C, Kadin ME, Bensussan A, Bagot M, Michel L. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large cell lymphoma. Br J Dermatol, 2016 Apr 1. doi: 10.1111/bjd.14626.
  • Brun C, Maginiot F, Cras A, Wong H, Ly Ka So S, Larghero J, Bensussan A, Oddos T, Michel L. Intrinsically aged dermal fibroblasts fail to differentiate into adipogenic lineage. Exp Dermatol, 2016 May 19. doi: 10.1111/exd.13080.
  • De Masson A, Giustiniani J, Marie-Cardine A, Bouaziz JD, Dulphy N, Gossot D, Validire P, Tazi A, Garbar C, Bagot M, Merrouche Y, Bensussan A. Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes. Oncoimmunology. 2016 Jan 13;5(5):e1127493. doi: 10.1080/2162402X.2015.1127493.
  • Merrouche Y, Fabre J, Cure H, Garbar C, Fuselier C, Bastid J, Antonicelli F, Al-Daccak R, Bensussan A, Giustiniani J. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells. Oncotarget. 2016 Jul 23. doi: 10.18632/oncotarget.10804.
  • Vallarelli AF, Rachakonda PS, André J, Heidenreich B, Riffaud L, Bensussan A, Kumar R, Dumaz N. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget. 2016 Jul 16. doi: 10.18632/oncotarget.10634. [Epub ahead of print]
  • Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M, Al-Dacak R. Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. Int J Mol Sci, 2016 Aug 30;17(9). pii: E1433. doi: 10.3390/ijms17091433. Review.
  • Chalick M, Jacobi O, Pichinuk E, Garbar C, Bensussan A, Meeker A, Ziv R, Zehavi T, Smorodinsky NI, Hilkens J, Hanisch FG, Rubinstein DB, Wreschner DH MUC1-ARF-A Novel MUC1 Protein That Resides in the Nucleus and Is Expressed by Alternate Reading Frame Translation of MUC1 mRNA. PLoS One. 2016 Oct 21;11(10):e0165031. doi: 10.1371/journal.pone.0165031
  • Brun C, Ly Ka So S, Maginiot F, Bensussan A, Michel L, Larghero J, Wong H, Oddos T, Cras A. Intrinsically aged dermal fibroblasts fail to differentiate into adipogenic lineage. Exp Dermatol, 2016 Nov;25(11):906-909. doi: 10.1111/exd.13080.
  • Lepelletier C, Bengoufa D, Lyes Z, de Masson A, Chasset F, Jachiet M, Michonneau D, Robin M, Peffault de Latour R, Sicre de Fontbrune F, Tandjaoui-Lambiotte Y, Bensussan A, Rybojad M, Tazi A, Bagot M, Socié G, Bergeron A, Bouaziz JD. Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation. JAMA Dermatol, 2016 Nov 16. doi: 10.1001/jamadermatol.2016.3976. [Epub ahead of print]
  • Fabre J, Giustiniani J, Antonicelli F, Merrouche Y, Bensussan A. IL-17 and triple negative breast cancer. MOJ Immunology. 2016, 3(6) : 00110. doi :10.15406/moji.2016.03.00110
  • Lédée N, Prat-Ellenberg L, Chevrier L, Balet R, Simon C, Lenoble C, Irani EE, Bouret D, Cassuto G, Vitoux D, Vezmar K, Bensussan A, Chaouat G, Petitbarat M. Uterine immune profiling for increasing live birth rate: A one-to-one matched cohort study. J Reprod Immunol. 2016 Nov 24;119:23-30. doi: 10.1016/j.jri.2016.11.007
  • Delyon J, Servy A, Laugier F, André J, Ortonne N, Battistella M, Mourah S, Bensussan A, Lebbé C, Dumaz N. PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.469. [Epub ahead of print]
  • Hurabielle C, Thonnart N, Ram-Wolff C, Sicard H, Bensussan A, Bagot M, Marie-Cardine A. Usefulness of KIR3DL2 to Diagnose, Follow-Up and Manage the Treatment of Sézary Syndrome Patients. Clin Cancer Res. 2017 Jan 24. pii: clincanres.3185.2016. doi: 10.1158/1078-0432.CCR-16-3185.
  • de Masson A, Bouaziz JD, Le Buanec H, Robin M, O'Meara A, Parquet N, Rybojad M, Hau E, Monfort JB, Branchtein M, Michonneau D, Dessirier V, Sicre de Fontbrune F, Bergeron A, Itzykson R, Dhédin N, Bengoufa D, Peffault de Latour R, Xhaard A, Bagot M, Bensussan A, Socié G. CD24hiCD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood. 2015 Jan 20. pii: blood-2014-09-599159. [Epub ahead of print]
  • Mombelli S, Kwiatkowski F, Abrial C, Wang-Lopez Q, de Boissieu P, Garbar C, Bensussan A, Curé H. Prognostic Factors in Operable Breast Cancer Treated with Neoadjuvant Chemotherapy: Towards a Quantification of Residual Disease. Oncology. 2015 Jan 8. [Epub ahead of print]
  • Rahmati M, Petitbarat M, Dubanchet S, Bensussan A, Chaouat G, Ledee N. Colony Stimulating Factors 1, 2, 3 and early pregnancy steps: from bench to bedside. J Reprod Immunol, 2015 Feb 11. pii: S0165-0378(15)00023-6. doi: 10.1016/j.jri.2015.01.005. [Epub ahead of print]
  • Schmitt C, Sako N, Bagot M, Bensussan A. Authors' reply. Am J Pathol, 2015 Apr;185(4):1168. doi: 10.1016/j.ajpath.2015.02.001.
  • de Masson A, Socié G, Bagot M, Bensussan A, Bouaziz JD. Deficient regulatory B cells in human chronic graft-versus-host disease. Oncoimmunology. 2015 Apr 1;4(7):e1016707. eCollection 2015 Jul.
  • Mombelli S, Cochaud S, Merrouche Y, Garbar C, Antonicelli F, Laprevotte E, Alberici G, Bonnefoy N, Eliaou JF, Bastid J, Bensussan A, Giustiniani J. IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells. Sci Rep. 2015 Jul 8;5:11874. doi: 10.1038/srep11874.
  • Bonnefoy N, Bastid J, Alberici G, Bensussan A, Eliaou JF. CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression. Oncoimmunology. 2015 Feb 3;4(5):e1003015. eCollection 2015 May.
  • Garbar C, Mascaux C, Giustiniani J, Salesse S, Debelle L, Antonicelli F, Merrouche Y, Bensussan A. Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway. Int J Clin Exp Pathol, 2015 May 1;8(5):4344-55. eCollection 2015.
  • Laugier F, Finet-Benyair A, André J, Rachakonda PS, Kumar R, Bensussan A, Dumaz N. RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma. Oncotarget. 2015 Sep 29;6(29):28120-31. doi: 10.18632/oncotarget.4866.
  • Sicard H, Bonnafous C, Morel A, Bagot M, Bensussan A, Marie-Cardine A. A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. Oncoimmunology. 2015 Jun 1;4(9):e1022306. eCollection 2015 Sep.
  • Engel P, Boumsell L, Balderas R, Bensussan A, Gattei V, Horejsi V, Jin BQ, Malavasi F, Mortari F, Schwartz-Albiez R, Stockinger H, van Zelm MC, Zola H, Clark G. CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology. J Immunol, 2015 Nov 15;195(10):4555-63. doi: 10.4049/jimmunol.1502033.
  • Chasset F, Le Buanec H, Sicre de Fontbrune F, de Masson A, Rivet J, Bergeron A, Bagot M, Socié G, Bensussan A, Bouaziz JD. Evidence of Th1, Th17 and Tc17 cells in psoriasiform chronic graft-versus-host disease. Exp Dermatol, 2016 Jan;25(1):64-5. doi: 10.1111/exd.12857. Epub 2015 Nov 2.
  • de Masson A, Guitera P, Brice P, Moulonguet I, Mouly F, Bouaziz JD, Battistella M, Madelaine I, Roux J, Ram-Wolff C, Cayuela JM, Bachelez H, Bensussan A, Michel L, Bagot M. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014 Jan 17. doi: 10.1111/bjd.12690.
  • Dulphy N, Henry G, Hemon P, Khaznadar Z, Dombret H, Boissel N, Bensussan A, Toubert A. Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. Br J Haematol, 2014 Feb 12. doi: 10.1111/bjh.12774.
  • Bouaziz J-D, de Masson A, Bagot M, Bensussan A. IL-10 Producing Regulatory B cells: Where Are We? MOJ Immunol, 2014, 1(1): 00003
  • Hu HH, Benfodda M, Dumaz N, Gazal S, Descamps V, Bourillon A, Basset-Seguin N, Riffault A, Ezzedine K, Bagot M, Bensussan A, Saiag P, Grandchamp B, Soufir N. A large french case-control study emphasizes the role of rare Mc1R variants in melanoma risk. Biomed Res Int, 2014;2014:925716. doi: 10.1155/2014/925716. Epub 2014 Apr 10.
  • Ghazi B, Thonnart N, Bagot M, Bensussan A, Marie-Cardine A. KIR3DL2/CpG ODN Interaction Mediates Sézary Syndrome Malignant T Cell Apoptosis. J Invest Dermatol, 2014 Jul 9. doi: 10.1038/jid.2014.286.
  • Sako N, Schiavon V, Bounfour T, Dessirier V, Ortonne N, Olive D, Ram-Wolff C, Michel L, Sicard H, Marie-Cardine A, Bagot M, Bensussan A, Schmitt C. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin. Cytometry A, 2014 Jul 18. doi: 10.1002/cyto.a.22512.
  • Bastid J, Bonnefoy N, Eliaou JF, Bensussan A. Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis. Oncoimmunology. 2014 Mar 27;3:e28273. eCollection 2014.
  • Moins-Teisserenc H, Daubord M, Clave E, Douay C, Félix J, Marie-Cardine A, Ram-Wolff C, Maki G, Beldjord K, Homyrda L, Michel L, Bensussan A, Toubert A, Bagot M. CD158k Is a Reliable Marker for Diagnosis of Sézary Syndrome and Reveals an Unprecedented Heterogeneity of Circulating Malignant Cells. J Invest Dermatol, 2014 Aug 26. doi: 10.1038/jid.2014.356.
  • Bouaziz JD, de Masson A, Le Buanec H, Bagot M, Bensussan A. [Update on regulatory B cells]. Med Sci (Paris), 2014 Aug-Sep;30(8-9):721-4. doi: 10.1051/medsci/20143008002.
  • Ruocco MG, Chaouat G, Florez L, Bensussan A, Klatzmann D. Regulatory T-cells in pregnancy: historical perspective, state of the art, and burning questions. Front Immunol, 2014 Aug 21;5:389. doi: 10.3389/fimmu.2014.00389. eCollection 2014.
  • Sako N, Dessirier V, Bagot M, Bensussan A, Schmitt C.HACE1, a Potential Tumor Suppressor Gene on 6q21, Is Not Involved in Extranodal Natural Killer/T-Cell Lymphoma Pathophysiology. Am J Pathol, 2014 Sep 5. pii: S0002-9440(14)00429-5. doi: 10.1016/j.ajpath.2014.07.011.
  • Brun C, Demeaux A, Guaddachi F, Jean-Louis F, Oddos T, Bagot M, Bensussan A, Jauliac S, Michel L. T-Plastin Expression Downstream to the Calcineurin/NFAT Pathway Is Involved in Keratinocyte Migration. PLoS One, 2014 Sep 16;9(9):e104700. doi: 10.1371/journal.pone.0104700. eCollection 2014.
  • Brun C, Maginiot F, Cras A, Serrano J, Wong H, Larghero J, Bensussan A, Oddos T, Michel L. Modifications phénotypiques et fonctionnelles des fibroblastes dermiques primaires liées à l’âge. Ann Dermatol Venereol, 2014 Jun;141(6-7 Suppl 2):S94. doi: 10.1016/j.annder.2014.04.166.
  • Rahmati M, Petitbarat M, Dubanchet S, Bensussan A, Chaouat G, Ledee N. Granulocyte-colony stimulating factor related pathways tested on an endometrial ex-vivo model. PLoS One, 2014 Oct 2;9(9):e102286. doi: 10.1371/journal.pone.0102286. eCollection 2014.
  • Ibarrola-Villava M, Kumar R, Nagore E, Benfodda M, Guedj M, Gazal S, Hu HH, Guan J, Rachkonda PS, Descamps V, Basset-Seguin N, Bensussan A, Bagot M, Saiag P, Schadendorf D, Martin-Gonzalez M, Mayor M, Grandchamp B, Ribas G, Soufir N. Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition. Int J Cancer, 2014 Oct 10. doi: 10.1002/ijc.29257.
  • Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, Bonnafous C, Rossi B, Bléry M, Paturel C, Bensussan A, Bagot M, Sicard H. IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma. Cancer Res, 2014, 74 (21):6060-70. doi: 10.1158/0008-5472.
  • Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF. Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity. Cancer Immunol Res, 2014, 74 (21):6060-70. doi: 10.1158/0008-5472.
  • Thonnart N, Caudron A, Legaz I, Bagot M, Bensussan A, Marie-Cardine A. KIR3DL2 is a coinhibitory receptor on Sézary syndrome malignant T cells that promotes resistance to activation-induced cell death. Blood. 2014 Nov 20;124(22):3330-2. doi: 10.1182/blood-2014-09-598995.
  • Bourillon A, Hu HH, Hetet G, Lacapere JJ, André J, Descamps V, Basset-Seguin N, Ogbah Z, Puig S, Saiag P, Bagot M, Bensussan A, Grandchamp B, Dumaz N, Soufir N Genetic variation at KIT locus may predispose to melanoma. Pigment Cell Melanoma Res, 2013, 26(1):88-96. doi: 10.1111/pcmr.12032.
  • Michel L, Jean-Louis F, Begue E, Bensussan A, Bagot M. Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sezary syndrome diagnosis. Blood. 2013, 121(8):1477-8. doi: 10.1182/blood-2012-10-460535.
  • Clark DA, Rahmati M, Gohner C, Bensussan A, Markert UR, Chaouat G. Seminal plasma peptides may determine maternal immune response that alters success or failure of pregnancy in the abortion-prone CBAxDBA/2 model. J Reprod Immuno, 2013, May 20. doi:pii: S0165-0378(13)00052-1. 10.1016/j.jri.2013.03.006.
  • Garbar C, Mascaux C, Curé H, Bensussan A. Muc1/Cd227 immunohistochemistry in routine practice is a useful biomarker in breast cancers. J Immunoassay Immunochem, 2013, 34(3):232-45. doi: 10.1080/15321819.2012.699491.
  • Bonnet MC, Bagot M, Bensussan A. Apoptotic and necroptotic cell death in cutaneous inflammation. Eur J Dermatol, 2013 Apr 9. [Epub ahead of print]
  • Bouaziz JD, Buanec HL, Zagury D, Bagot M, Bensussan A. Update on the use of active anti-cytokine therapies with kinoid vaccines for the treatment of inflammatory diseases. Med Sci (Paris). 2013, 29(6-7):669-70. doi: 10.1051/medsci/2013296023.
  • Tardieu M, Rybojad M, Peffault de Latour R, Robin M, de Masson A, Xhaard A, Le Buanec H, Parquet N, Sicre de Fontbrune F, Bergeron A, Scieux C, Dessirier V, Bensussan A, Bagot M, Socié G, Bouaziz JD. Localized edema with sclerodermatous evolution: a possible form of skin chronic graft-versus-host disease associated with endothelial activation. Blood. 2013, 122(3):463-5. doi: 10.1182/blood-2013-03-488148.
  • Schneider P, Plassa LF, Ratajczak P, Leboeuf C, Verneuil L, Battistella M, Bensussan A, Bagot M, Janin A. NKp46-Specific Expression on Skin-Resident CD4+ Lymphocytes in Mycosis Fungoides and Sézary Syndrome. J Invest Dermatol, 2013 Jul 30. doi: 10.1038/jid.2013.321.
  • Schmitt C, Marie-Cardine A, Bagot M, Bensussan A. Natural killer reprogramming in cutaneous T-cell lymphomas: Facts and hypotheses. World J Immunol, 2013, 3(1): 1-6. 2013 March 27. doi: 10.5411/wji.v3.i1.1.
  • Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Curé H, Mascaux C, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A, Bastid J. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep. 2013 Dec 9;3:3456. doi: 10.1038/srep03456.
  • Thonnart N, Ram-Wolff C, Bagot M, Bensussan A, Marie-Cardine A. Aberrant expression of CD56 by circulating Sézary syndrome malignant T lymphocytes. World J Immunol, 2013, 27; 3(3): 68-71. doi:10.5411/wji.v3.i3.68.
  • Begue E, Michel L, Jean-Louis F, Bagot M, Bensussan A. Promotor hypomethylation and expression of PLS3 in human Sezary lymphoma cells. SOJ Immunol, 2013, 1(1).
  • Bensussan A. Introduction. In immunology of pregnancy 2013. Editors : G. Chaouat, O. Sanda & N. Ledée. Bentham e-books. Bentham Science publishers. United Arab Emirates

Patents (2013-present)

  • 2016 Invariant FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
  • 2016 Ex vivo generation of γδ FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
  • 2016 Ex vivo generation of MHC II restricted CD4+ FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
  • 2016 Immunotherapeutic uses of ex vivo generated FoxP3+ regulatory T cells, US patent, 5 august 2016
  • 2016 Monoclonal antibodies binding to the CD160 transmembrane isoform. EP 16306392.8, 25 october 2016
  • 2016 Combinations therapies for treatment of cancer. EP 16305540, 10 may 2016. Licensed to OREGA Biotech
  • 2015 Antibodies having specificity to myosin 18A and uses thereof. EP 15306108, 7 july 2015
  • 2015 Methods and pharmaceutical compositions for the treatment of BRAF inhibitor resistant melanomas. EP 15306865, 25 november 2015
  • 2013 KIR3DL2 is a biomarker and therapeutic target useful for respectively preventing and treating a subset of peripheral T-cell lymphomas. PCT/EP2013/061107, 29 may 2013
  • 2013 IL-17 antagonist antibodies. EP 13731758.2, 25 june, 2013 Licensed to OREGA Biotech

Biotechnology company

  • 2010/- OREGA-Biotech, 69000 Ecully, France
  • 2017/- Alderaan Biotechnology, 75005 Paris